Cost and cost-effectiveness of a simplified treatment model with direct-acting antivirals for chronic hepatitis C in Cambodia by Walker, Josephine G et al.
                          Walker, J. G., Mafirakureva, N., Iwamoto, M., Campbell, L. S., San
Kim, C., Hastings, R., Doussett, J-P., Le Paih, M., Balkan, S.,
Marquardt, T., Maman, D., Lorec, A., Coast, J., & Vickerman, P. T.
(2020). Cost and cost-effectiveness of a simplified treatment model
with direct-acting antivirals for chronic hepatitis C in Cambodia. Liver
International. https://doi.org/10.1111/liv.14550
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1111/liv.14550
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://onlinelibrary.wiley.com/doi/full/10.1111/liv.14550. Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Liver International. 2020;00:1–11.    |  1wileyonlinelibrary.com/journal/liv
 
Received: 24 October 2019  |  Revised: 1 May 2020  |  Accepted: 24 May 2020
DOI: 10.1111/liv.14550  
O R I G I N A L  A R T I C L E
Cost and cost-effectiveness of a simplified treatment model 
with direct-acting antivirals for chronic hepatitis C in Cambodia
Josephine G. Walker1  |   Nyashadzaishe Mafirakureva1 |   Momoko Iwamoto2,3 |   
Linda Campbell1 |   Chamroeun San Kim3 |   Reuben A. Hastings1 |    
Jean-Philippe Doussett3 |   Mickael Le Paih3 |   Suna Balkan3 |   Tonia Marquardt3 |   
David Maman2 |   Anne Loarec2 |   Joanna Coast1 |   Peter Vickerman1,4
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd
Funding information Funding for this study was provided by Unitaid (https://unita id.org/) and Médecins Sans Frontières (MSF, https://www.msf.org/). A grant from Unitaid (SPHQ14-
LOA-217) financed parts of this study but did not play any role in the study design or in its implementation. PV acknowledges support from the NIHR Health Protection Research Unit in 
Evaluation of Interventions at the University of Bristol. Funders played no role in collection, analysis, interpretation of data, in the writing of the report, or in the decision to submit the 
manuscript for publication. The views expressed in this publication are those of the authors and do not necessarily represent the official position of MSF, NIHR, or the University of 
Bristol.  
Abbreviations: DAA, direct-acting antiviral; DALY, disability adjusted life years; DC, decompensated cirrhosis; FMC, full model of care; HCC, hepatocellular carcinoma; HCV, hepatitis  
C virus; ICER, incremental cost-effectiveness ratio; IQR, interquartile range; LMIC, low- and middle-income countries; MSF, Médecins Sans Frontières; QALY, quality adjusted life years; 
SMC, simplified model of care; SVR12, sustained virological response at 12 weeks after the end of treatment; WHO, World Health Organization; WTP, willingness to pay.
1Population Health Sciences, Bristol Medical 
School, University of Bristol, Bristol, England
2Epicentre, Paris, France
3Médecins Sans Frontières – France, Phnom 
Penh, Cambodia
4National Institute for Health Research, 
Health Protection Research Unit (NIHR 
HPRU) in Evaluation of Interventions, 
University of Bristol, Bristol, England
Correspondence Josephine G. Walker, 
Population Health Sciences, Bristol Medical 
School, University of Bristol, Bristol, 
England. Email: j.g.walker@bristol.ac.uk
Funding information
Unitaid, Grant/Award Number: SPHQ14-
LOA-217; Médecins Sans Frontières; NIHR 
HPRU in Evaluation of Interventions, Grant/
Award Number: IS-HPU-1112-10026
Handling editor: Gregory Dore 
Abstract
Background & Aims: In 2016, Médecins Sans Frontières established the first gen-
eral population Hepatitis C virus (HCV) screening and treatment site in Cambodia, 
offering free direct-acting antiviral (DAA) treatment. This study analysed the cost-
effectiveness of this intervention.
Methods: Costs, quality adjusted life years (QALYs) and cost-effectiveness of the in-
tervention were projected with a Markov model over a lifetime horizon, discounted at 
3%/year. Patient-level resource-use and outcome data, treatment costs, costs of HCV-
related healthcare and EQ-5D-5L health states were collected from an observational 
cohort study evaluating the effectiveness of DAA treatment under full and simplified 
models of care compared to no treatment; other model parameters were derived from 
literature. Incremental cost-effectiveness ratios (cost/QALY gained) were compared to 
an opportunity cost-based willingness-to-pay threshold for Cambodia ($248/QALY).
Results: The total cost of testing and treatment per patient for the full model of 
care was $925(IQR $668-1631), reducing to $376(IQR $344-422) for the simplified 
model of care. EQ-5D-5L values varied by fibrosis stage: decompensated cirrhosis 
had the lowest value, values increased during and following treatment. The simpli-
fied model of care was cost saving compared to no treatment, while the full model of 
care, although cost-effective compared to no treatment ($187/QALY), cost an addi-
tional $14 485/QALY compared to the simplified model, above the willingness-to-pay 
threshold for Cambodia. This result is robust to variation in parameters.
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1  | INTRODUC TION
The World Health Organization (WHO) estimated that 71 million peo-
ple were infected with the Hepatitis C virus (HCV) globally in 2015.1 
Most (80%) HCV infections are in low- and middle-income countries 
(LMIC),2 but fewer than 5% of these patients are diagnosed.3
HCV is a major contributor to liver cancer and overall cancer 
deaths in Cambodia and Asia.4,5 Southeast Asia has the second high-
est burden of viral hepatitis mortality globally.1 More than 11 million 
people are estimated to have antibodies to HCV in this region,6 with 
2.3% of Cambodians exposed to HCV.7
Direct-acting antivirals (DAAs) offer an effective cure for HCV with 
few side effects. Access to these medicines, however, has been limited 
by their high cost, alongside the cost of diagnostics and the infrastruc-
ture required for scaling up treatment.3,8 In Cambodia, healthcare expen-
diture per capita is low ($69 in 2012); of this 60% comes from patient 
out of pocket expenses.9 Despite limited funding, ongoing government 
health initiatives provide tuberculosis, malaria and HIV/AIDS treatment 
free at the point of care. However, there is no national HCV strategy, 
with procurement of HCV drugs left entirely to the private sector.
In 2016, in collaboration with the Ministry of Health, Médecins Sans 
Frontières (MSF) established the first general population HCV testing and 
treatment site in Phnom Penh, Cambodia, offering free DAA treatment. 
The initial model of care for HCV treatment, based on 2016 European 
Association for the Study of the Liver guidelines,11 was subsequently sim-
plified in 2017 by reducing the number of patient visits and treatment 
monitoring conducted, with data suggesting this did not adversely affect 
patient outcomes (cure rate and incidence of serious adverse events).10
In this study, we evaluate the cost-effectiveness of both the full 
and simplified models of care implemented by MSF. To our knowl-
edge, this is the first study to conduct a full costing and cost-ef-
fectiveness analysis of a real-world HCV treatment intervention in 
a LMIC. This includes Cambodian patient-level data on EQ-5D-5L 
health states for different HCV disease stages and the cost of 
healthcare for HCV-related liver disease.
2  | METHODS
This study evaluated the cost-effectiveness of MSF's HCV treatment 
program in Cambodia10 in terms of cost per quality adjusted life year 
(QALY) gained using a Markov state-transition model representing 
the lifetime disease progression of a cohort of HCV-infected patients. 
Model parameters, health state values and costs were based on data 
from the cohort of patients screened and treated as part of the pro-
gram, as well as from the literature. Compared to a counterfactual of 
no treatment, we evaluated two strategies implemented by MSF: the 
initial full model of care (FMC), and simplified model of care (SMC).
2.1 | Setting and models of care
Patient characteristics, costs and quality of life data were collected from 
an observational cohort study evaluating the ‘real-world’ effectiveness 
of DAAs for the treatment of chronic HCV infection in adults (≥18 years). 
This study was conducted at MSF's HCV clinic, embedded within the 
gastroenterology department of the Preah Kossamak Hospital in Phnom 
Penh.10 Clinic staff were employed by MSF, with a small number of 
nurses and doctors seconded from the Ministry of Health.
The FMC and SMC both included processes for HCV diagnosis and 
liver disease staging, following which patients either began treatment, 
were referred for further tests to determine eligibility or control comor-
bidities, or were determined to be ineligible for treatment.10 Treatment 
regimens were based on sofosbuvir with daclatasvir or sofosbuvir with 
ledipasvir, with sofosbuvir/daclatasvir used as a pan-genotypic regimen 
in the SMC. Each patient was tested for sustained virological response 
at 12 weeks after the end of treatment (SVR12) to determine if treat-
ment was successful. The SMC used point of care tests (SD Bioline and 
GeneXpert) for diagnostics while the FMC used an external lab for ELISA 
and PCR confirmation. In the SMC, compared to the FMC, the number 
of sessions where nurse-counsellors discussed risk factors, adherence 
and lifestyle education with patients were reduced (from ten to two), 
Conclusions: The simplified model of care was cost saving compared to no treatment, 
emphasizing the importance of simplifying pathways of care for improving access to 
HCV treatment in low-resource settings.
K E Y W O R D S
cost-effectiveness, direct-acting antiviral treatment, healthcare costs, hepatitis C, low-income 
population, Markov process, treatment costs
Lay Summary
• Access to treatment for Hepatitis C virus (HCV) has been 
limited in low and middle-income countries because of 
the high cost of drugs and complex treatment protocol.
• Médecins Sans Frontières screened and treated patients for 
HCV in Phnom Penh, Cambodia, with a simple treatment 
protocol with fewer visits (than standard of care), point of 
care testing and task shifting from doctors to nurses.
• The simple treatment protocol saved money and had 
better outcomes projected over the lifetime of the co-
hort patients compared to if they had not received HCV 
screening and treatment.
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genotype testing was eliminated, three blood tests for monitoring during 
treatment were removed, patient visits during treatment were reduced 
from eight to four, with some tasks shifted from doctors to nurses and 
pharmacists (Figure 1, Table S1). The FMC includes patients initiated on 
treatment from September 2016 through March 2017, and the SMC 
includes patients initiated on treatment from August 2017 through April 
2018. March to August 2017 was a transition phase in which the model 
of care was gradually simplified—this phase is not considered here.
Written consent was obtained from all patients. Ethics approval 
for this study was obtained from the French Comité de Protection 
des Personnes of Saint-Germain-en-Laye (reference: 16049) and the 
National Ethical Committee for Health Research of the Cambodian 
MoH (reference: 005 NECHR). Official permission for this study was 
obtained from the Director of Kossamak Hospital.
2.2 | Costing methods
The costs of HCV diagnosis and treatment were estimated from 
the provider's perspective in 2017 US dollars, using a retrospective 
cohort-based approach over a 9-month period (September 2016–
May 2017). Data on costs came from MSF's expenditure records and 
price lists, which were allocated to activities making up the FMC as 
described above, with subtotals calculated for clinic visits, labora-
tory tests, DAA and other medicines and diagnosis costs.
2.2.1 | Patient-level resource use
Detailed patient-level data on the numbers and types of visits and 
tests undertaken for patients receiving each model of care were 
collected from electronic individual patient records.12 Costs of case-
finding were included as the cost of testing patients who were not 
found to be chronically infected. Data on the quantity of DAAs and 
other medicines received by each patient during the intervention 
came from pharmacy dispensing records. Staff time was allocated 
for each activity through the use of staff time sheets completed over 
the course of one week by patient-facing staff, direct observation 
and interviews with staff and according to the number of patient 
interactions in the observation period.
2.2.2 | Valuation of resources
Valuation of the resources used in the intervention was based on 
detailed financial records provided by MSF using activity-based 
costing. The cost per activity within the intervention, for example 
the baseline treatment visit, was estimated as the sum of ingre-
dients (Table S5). These ingredients, such as cost per minute of 
doctor or counsellor time or cost of clinic facilities per patient visit, 
were estimated from the financial records during the observation 
period when the FMC was implemented. Activity cost estimates 
from the FMC during the observation period were adapted to 
estimate the costs of the SMC based on interviews with project 
staff to determine how activities and their ingredients differed be-
tween the models of care. Unit costs for medicines were derived 
using the 2017 MSF Access campaign negotiated costs for DAAs 
and other medications. The costs of laboratory tests contracted 
outside of the intervention were gathered from hospital price lists 
and from invoices billed to MSF (Table S6). In the base case we 
exclude costs specific to MSF and replace staff costs for inter-
national staff with what local staff would be paid by MSF for the 
F I G U R E  1   Summary of differences between full (top, blue) and simplified (bottom, orange) models of care at each phase of the screening 
and treatment process. Full details included in Table S1
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same role. More details on costing methods can be found in the 
supplementary material (Methods S1).
2.2.3 | Cost of hepatitis C-related disease
Information on patient access to healthcare for HCV-related liver dis-
ease prior to treatment was gathered through a resource-use ques-
tionnaire administered to a subset (n = 144, liver disease stages F0-F4) 
of diagnosed patients at their initial visit. The questionnaire asked 
patients to recall the number of hospital inpatient or outpatient and 
clinic visits (health system contacts) in the 6 months prior to coming 
to the MSF clinic. We assumed that contacts in 6 months represented 
half of the annual number of contacts. For each type of visit, the pa-
tient was further asked to recall the reason and the price paid for the 
most recent visit. We use patient-reported costs to represent the cost 
of care in the base case because prior to the MSF program, all relevant 
costs would be the responsibility of the patient (Methods S2).
F I G U R E  2   Schematic of Markov 
model showing how patients progress 
through infection and liver disease 
states. Dashed lines indicate initiation on 
treatment. I = infected; T = on treatment; 
S = susceptible. Baseline mortality occurs 
according to cohort age, with equal death 
rates for all compartments (not shown in 
figure)
TA B L E  1   Model parameters and their distributions for the probabilistic sensitivity analysis
Variable Base-case value Distribution in PSA
Distribution 
parameter(s)a  Source
Fibrosis progression (annual transition probability)
Mild fibrosis (F0) to Mild fibrosis 
(F1)
0.117 Normal 0.005 36
Mild fibrosis (F1) to Moderate 
fibrosis (F2)
0.085 Normal 0.004 36
Moderate fibrosis (F2) to Moderate 
fibrosis (F3)
0.121 Normal 0.0046 36
Moderate fibrosis (F3) to Severe 
fibrosis (F4)
0.115 Normal 0.004 36
F4 to DC 0.039 Beta 14.6, 360.2 (95% CI 
0.022-0.046)
37
F4 or DC to HCC 0.014 Beta 1.9, 136.1 (95% CI 
0.0016- 0.039)
37
F4 to DC after SVR achieved 0.070 * F4 to DC Triangle [95% CI of base case 0.03-




F4 or DC to HCC after SVR 
achieved
0.230 * F4 or DC to 
HCC
Triangle [95% CI of base case 0.16-




Liver-related mortality (annual transition probability)
DC to liver death 0.130 Beta 147.03, 983.97 (95% CI 
0.11-0.15)
37
HCC to liver death 0.430 Triangle 0.40,0.44 37
Viral re-infection (annual transition 
probability)
0 Triangle 0, 0, 0.01
SVR12 rate Cohort
Full 0.968 Binomial 0.968, 624 (95% CI 
0.950-0.980)
Simplified 0.940 Binomial 0.940, 1324 (95% CI 
0.925-0.952)
Cohort initial age 55.9 Normal 10.6 Cohort
aDistribution parameters for PSA: Normal: standard deviation; Triangle: lower, peak, upper; Beta: α [shape1], β [shape2]; Binomial: proportion, sample size. 
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Patients with fibrosis stage F0 (no liver damage) were assumed 
to represent a baseline number of health system contacts (visits) 
for those without liver disease, with the number of visits for more 
advanced disease states being modelled using Poisson regression 
from the questionnaire data. The patient-reported mean cost per 
visit was then multiplied by the modelled annual number of visits to 
calculate the annual cost of liver disease care for each fibrosis stage 
(Methods S2). Estimates of the yearly cost of decompensated cirrho-
sis (DC) and hepatocellular carcinoma (HCC) were based on reviews 
of patient records in three hospitals analysed and adjusted through a 
WHO-facilitated expert discussion. In the base case, we assume that 
70% of patients with these disease stages access this care based on 
expert opinion (Methods S2). The estimated costs of healthcare are 
assumed to apply to infected patients of all disease stages and cured 
patients with F4, DC and HCC.
2.3 | Simulation model
The costs and outcomes of each treatment strategy were projected 
for a cohort of diagnosed patients using a Markov model with annual 
time steps. The cohort is defined by the number of individuals diag-
nosed with chronic HCV infection, allocated to liver disease severity 
categories according to the distribution found among patients who 
had a fibrosis score recorded. The model schematic (Figure 2) shows 
progression characterized by different stages of liver disease sever-
ity. The modelled health states include stages for METAVIR fibrosis 
scores F0, F1, F2, F3, F4 (cirrhosis),14 DC and HCC. Each of the seven 
modelled health states has three possible HCV states (infected, on 
treatment and cured/susceptible). Patients are modelled to receive 
treatment in the first year of the simulation, with the proportion 
treated in each fibrosis stage matching the treatments in the inter-
vention data.
Liver disease-related mortality (assumed to occur in the DC and HCC 
states only) and background age-dependent mortality (Figure S1) were 
modelled as absorbing health states. The number of liver transplants per-
formed in Cambodia is negligible, and so was not modelled. The model 
was implemented in R version 3.6.1 using the heemodpackage.15,16
2.3.1 | Disease progression rates
Parameter values for progression through disease states were 
sourced from previous studies (Table 1). Each patient started in 
one of seven liver disease states according to the distribution in 
the cohort. At the end of each cycle, patients either remain in the 
same state, move into a more advanced disease state or die from 
background or HCV-related mortality (Figure 2). In the base case 
we assume there is no re-infection following curative treatment. 
The SVR12 rate was calculated for the FMC and SMC from patients 
who were due to complete treatment at least 12 weeks before the 
data export date (17 July 2018), with those not tested for SVR12 for 
any reason, including loss to follow-up and death, counted as not 
achieving SVR12 (treatment failure). Patients who fail treatment re-
turn to the infected states and are assumed to face the same risks of 
liver disease progression as untreated patients, while cured patients 
move to a susceptible compartment in the same liver disease stage 
they were treated in. Being cured stops disease progression in pre-
cirrhotic patients while it is slowed in cirrhotic patients.
2.4 | Outcomes
The Khmer version of EQ-5D-5L17 was used to collect health-related 
quality of life measures for patients (4934 total individuals) with 
chronic HCV infection prior to treatment initiation, during treatment 
and at the SVR12 visit after treatment. Where multiple records were 
available for a patient at a given treatment stage, we combined these 
into a single measure using a time-weighted average. Patients who 
failed treatment (n = 62) were not included in the after-treatment 
analysis. EQ-5D-5L measures were stratified by fibrosis stage and 
converted to health state values using the EQ-5D-5L value set avail-
able for Indonesia,18 as this is the closest country in the same World 
Bank income group where a value set is available. Health state values 
for each model compartment were estimated using a linear mixed-
effects model with patient as a random effect and fibrosis stage and 
treatment stage as fixed effects.
2.5 | Cost-effectiveness analysis
We evaluated the cost-effectiveness of the FMC and SMC com-
pared to no HCV treatment in the study population. The model was 
run for 100 years to cover the full lifetime of the cohort, with a 
baseline discount rate of 3% for both future costs and outcomes.19 
Cost-effectiveness was evaluated in terms of lifetime costs per 
QALY gained, or the incremental cost-effectiveness ratio (ICER) 
for each strategy. This was compared to an empirical opportunity 
cost-based willingness-to-pay (WTP) threshold of $248 per QALY 
gained20 and to the commonly used threshold of GDP per capita 
($1270).21
2.6 | Sensitivity analysis
We accounted for uncertainty in key parameters by conducting a 
probabilistic sensitivity analysis, in which 1000 parameter sets were 
sampled from their statistical distributions (Table 1). The cost of 
treatment for each fibrosis stage was varied according to the data in 
a triangular distribution of the median and inter-quartile range (IQR, 
Table S4). Cost of care was varied in a triangular distribution accord-
ing to the bootstrapped 95% confidence interval for F1-F4 (Table 2) 
and according to the range of consensus values for DC and HCC. 
Health state values were varied in a triangular distribution of the 
mean and 95% confidence interval for each fibrosis stage and time 
point (Table 3).
6  |     WALKER Et AL.
In addition, we conducted one-way sensitivity analyses by vary-
ing key parameters in the model to minimum or maximum values to 
test model assumptions. This included changing the DAA cost to be 
$120 per treatment course for every patient instead of varying by 
individual, removing or doubling the cost of care for liver disease, 
using WHO-CHOICE estimates of the cost of care instead of pa-
tient-reported costs for F0-F422 (Methods S2) and varying the per-
centage of end stage liver disease patients (DC or HCC) accessing 
care from 70% to 40% or 100%. In addition, we analyse the inclusion 
of MSF-specific indirect costs, alternative discount rates of 0% or 
7%, reducing the time horizon to 10 years from 100 years, allowing 
for re-infection with HCV at 1% or 10% per year (except for patients 
with HCC) and changing the initial age of the cohort to 45 or 65. 
We evaluated how the cost-effectiveness of treatment would vary 
if screening yielded antibody prevalences of 2.3% (the national es-
timate7), 10% or 30%, compared to 65% as observed in the cohort. 
For these sensitivity analyses, we assumed 72% chronic infection 
among those that are antibody positive, as found in the cohort. We 
also present results using an alternative EQ-5D-5L value set from 
Thailand23 and disability values from the 2016 Global Burden of 
Disease study to estimate health state values in the form of disability 
adjusted life years (DALY, Table S10). We evaluate the effect of pa-
tients having equal treatment rate across all fibrosis stages, match-
ing the overall treatment rate in the cohort of 64%, or if the cost 
of treatment is assumed to be the overall average mean cost rather 
than varying by fibrosis stage. We evaluate the result if core antigen 
testing ($20/test24) was used in a one-step screening process (no 
antibody testing) or to replace the confirmatory test and if the SVR 
rates for both models of care were reduced by 20% (to 75% and 77% 
for the SMC and FMC respectively).
3  | RESULTS
3.1 | Cohort treatment outcomes
Of 15 112 patients screened, 7131 patients were diagnosed 
with chronic HCV (47%), 6831 referred to care and 4550 (64% of 
diagnosed) initiated treatment between 19 September 2016 and 30 
April 2018 (Figure S4). The mean age of those treated was 55.9 (SD 
10.6) years and 57% were female. Patients with cirrhosis (F4), DC 
or HCC made up 32.8% of diagnosed patients and 44.5% of treated 
patients (Table S2).
Under the FMC and SMC, 624 and 1324 patients initiated treat-
ment and were followed-up to at least 12 weeks post treatment 
respectively. These individuals were included in the costing and out-
comes analysis, while patients treated during the transitional phase 
between the models of care were excluded from analysis (Figure 
S4). Characteristics of patients treated under each model of care are 
presented in Table S3. In the FMC, 96.8% (95% confidence inter-
val 95.0%-98.0%) of patients achieved SVR12, while 94.0% (92.5%-
95.2%) achieved SVR12 in the SMC. Treatment regimens were based 
on sofosbuvir with daclatasvir in 56% and 98% of patients in the 
FMC and SMC, respectively, with the remaining treatments being 
sofosbuvir with ledipasvir.
3.2 | Costs of HCV treatment
The median total cost of HCV testing and treatment for the FMC 
was $925 (IQR $668-1,631) and $376 (IQR $344-422) for the SMC 
(Figure 3, Table S4). The biggest contributor to the overall cost in 
both models was DAA costs, making up 26% and 42% of the total 
treatment cost for the FMC and SMC respectively.
3.3 | Cost of hepatitis C-related disease
The number of health system contacts reported in the resource-
use questionnaire is presented in Table 2 and Figure S2. The mean 
cost per visit was $72.34 (bootstrapped 95% CI $49.35-$110.81) 
and the annual cost of care ranged from $39.06 for F0 to $226.42 
for F4 (Table 2). From the WHO-facilitated expert discussion, the 
annual cost of inpatient care for a patient with decompensated cir-
rhosis was $347 (varying from $236 to $457 in provincial versus 
national hospital settings) and for hepatocellular carcinoma was 
TA B L E  2   Reported health system contacts by fibrosis stage, with Poisson modelled annual number of health system contacts, in addition 
to the contacts by an F0 patient
Disease stage N
Mean, (IQR) reported health system 
contacts in last 6 months
Modelled annual number of health system 





F0 17 1.0, (0-1) 0 $0.00
F1 42 1.2, (0-1) 0.54 (0.016-1.19) $39.06 
($9.63-$84.65)
F2 29 1.8, (0-2) 1.22 (0.032-3.05) $88.25 
($19.27-$227.88)
F3 14 3.4, (0-6) 2.07 (0.048-5.94) $149.74 
($48.93-$418.25)
F4 37 2.3, (0-3) 3.13 (0.065-10.45) $226.42 
($73.91-$728.10)
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$424 ($368-$576). The alternative estimates based on WHO-
CHOICE gave an annual cost of care for F0-F3 of $28.27 and 
$216.51 for F4.
3.4 | Health state values
Health state values generated through EQ-5D-5L varied by fibro-
sis stage and treatment status. The health state value increased 
by 0.039 (95% CI 0.032-0.046) during treatment and 0.068 (95% 
CI 0.061-0.075) after treatment, compared to pretreatment levels. 
Patients with DC had the lowest health state values, 0.11 (95% CI 
0.090-0.13) lower than patients in F0, while patients with HCC had 
health state values 0.083 (95% CI 0.050-0.12) lower than patients in 
F0. Fitted health state values for each disease and treatment state 
used in the model are shown in Table 3. The health profiles (propor-
tion of individuals with each level for the five dimensions) reported 
in EQ-5D-5L are presented in Tables S7-S9.
3.5 | Cost-effectiveness
The FMC compared to no treatment was cost-effective ($187/QALY) 
compared to the opportunity cost WTP threshold ($248) and GDP 
threshold ($1270). The SMC was cost-saving (−$91/QALY, Table 4) 
compared to no treatment. The incremental benefit of implementing 
the FMC compared to the SMC costs $14 485/QALY. These results 
are robust to parameter variation in the probabilistic sensitivity anal-
ysis, with 94.0% of runs for the SMC being cost-saving and 99.7% 
Disease stage
Health state value
Before treatment During treatment
After treatment 
(cured)
F0 0.86 (0.85-0.88) 0.90 (0.89-0.91) 0.93 (0.92-0.94)
F1 0.86 (0.85-0.87) 0.90 (0.89-0.91) 0.93 (0.92-0.94)
F2 0.85 (0.84-0.86) 0.89 (0.87-0.90) 0.92 (0.90-0.93)
F3 0.87 (0.86-0.87) 0.91 (0.90-0.91) 0.94 (0.93-0.94)
F4 0.85 (0.84-0.85) 0.88 (0.88-0.89) 0.91 (0.91-0.92)
DC 0.75 (0.74-0.77) 0.79 (0.77-0.81) 0.82 (0.80-0.84)
HCC 0.78 (0.75-0.81) 0.82 (0.79-0.85) 0.85 (0.82-0.88)
TA B L E  3   Health state values (mean 
and 95% CI) by disease stage and 
treatment time point estimated from 
mixed-effects model with patient as a 
random effect
F I G U R E  3   Median and interquartile range of overall cost of 
treatment (top) and median proportion of overall cost of treatment 
attributable to different activities (bottom) under the full and 


































DAA cost Laboratory cost Visit cost Screening cost Other costs
Components of cost of treatment
Strategy
Cost (USD) per capita QALY per capita ICER
Total Incremental Total Incremental
Cost/
QALY
No treatment $1,298 — 7.49 — Dominated
Simplified Model 
of Care
$1,185 −$113 8.72 1.24 −$91
Full model of care $1,534 $350 8.75 0.024 $14,485
TA B L E  4   Incremental cost-
effectiveness of full and simplified models 
of care for the base case. Time horizon is 
100 years and discount rate is 3%
8  |     WALKER Et AL.
being cost-effective compared to the opportunity cost threshold 
(Figure S3).
3.6 | Sensitivity analysis
When key model parameters are varied the SMC generally remains 
cost-saving compared to no treatment (Figure 4), while the FMC is 
never cost-effective compared to the SMC (Table S11). The only 
changes which make the SMC not cost-saving are reducing the cost 
of care for all HCV-related liver disease to $0 ($205/QALY), using 
WHO-CHOICE costs for F0-F4 liver disease care ($29/QALY), in-
creasing re-infection rate to 10% per year ($39/QALY), or reducing 
screening prevalence to 2.3% ($28/QALY), all of which are still cost-
effective compared to the opportunity cost WTP threshold ($248). 
The SMC would remain cost-saving at an antibody prevalence of 3% 
or a re-infection rate up to 6%/year.
4  | DISCUSSION
Our analyses suggest that an HCV testing and treatment interven-
tion undertaken among the general population in Cambodia could 
be cost-saving when a simplified model of care is used. This simpli-
fied model of care provides similar high rates of cure to the initially 
implemented but more costly full model of care.10 Although the full 
model of care resulted in a small incremental benefit of 0.03 QALYs 
per person compared to the simplified model, this occurred at ap-
proximately triple the cost per treatment, and was not cost-effective 
compared to the simplified model of care.
4.1 | Strengths and limitations
The main strength of this study is the use of detailed data from a 
real-life implementation of HCV testing and treatment in a LMIC, 
including a full activity-based costing analysis instead of expert 
opinion to calculate the costs of screening and treatment. We also 
surveyed patients directly about their healthcare resource use prior 
to seeking HCV treatment in order to estimate the cost of medi-
cal care for patients living with HCV; to our knowledge this is the 
first time this has been done in a LMIC. Unfortunately, these es-
timates are limited by the long recall period used, and reliance on 
patient-reported expenditure. This is likely to be an underestimate 
of the full costs of care, resulting in a conservative ICER. A better 
understanding of the proportion of individuals who access different 
F I G U R E  4   Deterministic sensitivity analysis showing simplified model of care ICER compared to no treatment when parameters are 
varied one at a time. Text on plot shows new parameter value where relevant. Solid vertical line shows baseline ICER of −$91/QALY, dotted 
line shows $0/QALY (cost-saving threshold), and dashed line shows opportunity cost threshold for Cambodia ($248/QALY). The full set of 















EQ−5D−5L health state values from Thailand value set
Equal cost of treatment by fibrosis stage
One step screening with core antigen test





Core antigen test instead of GeneXpert
Percentage of DC or HCC patients access care
Equal treatment by fibrosis stage
Reduce SVR rate by 20%
Initial cohort age
PCR instead of GeneXpert in SMC
Prevalence of HCV in screening (%)
WHO−CHOICE cost of care for HCV−related liver disease
Reinfection rate (annual %)
Cost of care for HCV−related liver disease
−400 −200 0 200
ICER per QALY gained (USD)
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levels of healthcare, and how this will change in the future, is crucial 
to improving the accuracy of cost-effectiveness estimates for HCV 
treatment.
Another strength is that we directly estimated health state utility 
weights for each stage of liver disease and treatment using EQ-5D-5L 
questionnaires collected from the treated population. Self-reported 
quality of life improved during treatment and at SVR12 as compared 
to baseline, similar to what has been observed in a cohort of patients 
treated with DAAs in Japan,25 but with our data adding important 
information for LMICs.
A main limitation of this analysis is that, because of a lack of 
information on current re-infection risk we did not account for 
changes in disease incidence over time in our analysis. However, 
as a result of the advanced age and fibrosis observed in our cohort 
of patients, it is likely that many individuals were infected decades 
ago rather than being at current risk of infection and re-infection. 
Including a constant re-infection rate made little difference to the 
result.
Furthermore, the population involved in this intervention were 
self-selecting, and were therefore highly motivated to receive 
treatment. The 65% antibody prevalence rate among screened 
patients indicates many were aware or suspected they were in-
fected with HCV. Globally, fewer than 5% of those infected with 
HCV are aware of their status,26 indicating that this high screen-
ing yield is not likely to be maintained once individuals who are 
aware of their status have been treated (warehousing effect). 
Importantly, though, our projections suggest the intervention 
remains cost saving even if the screening yield reduces to 3%, 
with the estimated prevalence for Cambodia being 2.3%.7 A new 
sero-prevalence study in rural Cambodia found similar results to 
the previous estimate, with 2.6% (95% CI 2.3-3.0) prevalence in 
people 18 years or older, and 5.1% (4.6%-5.7%) in those 45 years 
or older.27 This suggests that targeting screening towards older 
people would help the intervention to be cost-saving, while the 
intervention would remain highly cost-effective ($28/QALY) with 
no targeting.
The intervention implemented by MSF demonstrates the feasi-
bility and cost-effectiveness of a general population screening and 
treatment intervention for HCV implemented by an international 
NGO. If the intervention were expanded by the Ministry of Health 
or other local organizations, costs are likely to be different as MSF 
procured some equipment and consumables outside of Cambodia, 
and although they set local staff salaries based on competitive local 
rates, salaries may still vary by organization. To make a detailed im-
plementation plan for HCV screening and treatment, local organi-
zations can evaluate where their costs will differ from MSF. Also, 
the landscape of diagnostic tools and cost for HCV drugs are both 
rapidly changing as countries aim to achieve HCV elimination, so it 
is likely that new technologies will be available for consideration in 
future implementations.
Although we demonstrate that this intervention is cost-sav-
ing, the upfront cost of treatment with the simplified model of 
care ($311 excluding screening) for an estimated 270 000 chronic 
infections in Cambodia would be $84 million. The full cost of scaling 
up screening and treatment will be highly dependent on antibody 
screening yield, which can be maximized through targeting treat-
ment to groups known to be more likely to be infected, such as the 
older population.27
4.2 | Comparison with other studies
Previous evidence on the cost-effectiveness of treatment with DAA-
only regimens for HCV in LMIC is limited, but in agreement with our 
results. Studies in Egypt28 and India29-32 have found HCV screen-
ing and treatment to be cost-saving, and cost-effective in Lebanon33 
and Indonesia.34 The WHO Hep C Calculator,35 which allows a user 
to input the cost of treatment, finds HCV treatment (not including 
testing) in Cambodia to be cost-effective when default values are 
used and cost-saving when input values from this study are used. 
However, these previous models do not use data from a real-world 
intervention, while ours is the first to use data from a local treat-
ment intervention to estimate the costs of testing, treatment and 
healthcare, as well as quality of life utilities for different stages of 
HCV disease. Our analysis is therefore an important addition to the 
literature.
4.3 | Implications and conclusions
Much of the effort towards expanding access to HCV treatment in 
LMIC has focused on reducing and simplifying the cost of testing 
and DAA medication. In this cohort, simplification of the treatment 
pathway quadrupled the number of people that could be treated and 
cured,10 reduced the cost of treatment by two-thirds and resulted in 
the intervention becoming cost-saving. This remained so even if the 
prevalence of HCV was as low as 3%, suggesting this model of care 
could be used to expand screening and treatment across Cambodia. 
Although our study was implemented by MSF, the Ministry of Health 
in Cambodia and other LMIC can be empowered by these results 
to scale-up HCV treatment access using a simplified model of care 
relative to standard international guidelines.11 Urgent scale-up of 
treatment access for all infected individuals is necessary to prevent 
HCV-related mortality and reach HCV elimination as proposed by 
WHO.3
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